<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00255580</url>
  </required_header>
  <id_info>
    <org_study_id>C00-SD-104</org_study_id>
    <nct_id>NCT00255580</nct_id>
  </id_info>
  <brief_title>Medicinal Cannabis for Painful HIV Neuropathy</brief_title>
  <official_title>Placebo-Controlled, Double Blind Trial of Medicinal Cannabis in Painful HIV Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center for Medicinal Cannabis Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Center for Medicinal Cannabis Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if medicinal cannabis (marijuana) is safe and&#xD;
      effective for treating pain in individuals with HIV-associated distal, sensory-predominant&#xD;
      polyneuropathy (DSPN).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Peripheral neuropathy occurs in over 30% of patients with HIV infection, making it among the&#xD;
      most common neurological complications of HIV infection. Nucleoside analogues such as ddI and&#xD;
      d4T, key components of modern, potent, combination antiretroviral therapies (ART), are also&#xD;
      neurotoxic and contribute to the frequent occurence of painful neuropathy. By using treatment&#xD;
      with available non-narcotic analgesic and adjunctive pain medications, approximately half of&#xD;
      patients with painful HIV neuropathy obtain sufficient pain control.&#xD;
&#xD;
      On the first day each study week (active or placebo), participants will follow a specific&#xD;
      titration procedure to achieve the optimal dose. This optimal dose will then be continued for&#xD;
      the duration of the treatment week. Participants will undergo a 2-week washout period, after&#xD;
      which they crossover to the other arm (active or placebo) and will again repeat the dose&#xD;
      titration and dose maintenance procedures.&#xD;
&#xD;
      Comparison: Active cannabis doses ranging from 2-8% THC will be compared to placebo for the&#xD;
      reduction of neuropathic pain.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2001</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Descriptor Differential Scale (DDS)</measure>
    <time_frame>Baseline, Post-treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the use of opioid and non-opioid analgesics</measure>
    <time_frame>Post-Treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in measures of everyday functioning and subject-perceived quality of life</measure>
    <time_frame>Baseline, Post-Treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>Post-Treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse cognitive effects as assessed by neuropsychological testing.</measure>
    <time_frame>Baseline, Post-Treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Neuropathic Pain</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active cannabis (1-8% THC by weight)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo cannabis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Smoked cannabis</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented HIV infection&#xD;
&#xD;
          -  Meets clinical and electrodiagnostic criteria for HIV-associated DSPN at entry&#xD;
&#xD;
          -  Daily pain for at least three consecutive months with an average daily pain magnitude&#xD;
             score of at least 5 on the Descriptor Differential Scale&#xD;
&#xD;
          -  Inadequate pain relief with prior treatment for painful HIV neuropathy using drugs&#xD;
             from at least two different classes of pain-modifying agents (NSAIDS, low-potency&#xD;
             opioids, high-potency opioids, sodium channel blockers, other adjunctive pain&#xD;
             treatments)&#xD;
&#xD;
          -  Age 21-65 years&#xD;
&#xD;
          -  Stable use of opioid and non-opioid analgesic medications during the two weeks prior&#xD;
             to study entry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Positive urine toxicology screen for cannabinoids during the &quot;wash-in&quot; week prior to&#xD;
             initiating study treatment&#xD;
&#xD;
          -  Recent (i.e. during the month prior to study entry) history of marijuana use more than&#xD;
             twice a week&#xD;
&#xD;
          -  Previous psychosis with or intolerance to cannabinoids&#xD;
&#xD;
          -  A lifetime history (ever) of dependence on cannabis&#xD;
&#xD;
          -  Meeting criteria for alcohol or drug dependence within the last 12 months&#xD;
&#xD;
          -  Active, major psychiatric disorder likely, in the investigator's opinion, to interfere&#xD;
             with adherence to the study protocol&#xD;
&#xD;
          -  Active AIDS-defining opportunistic disease (a history of AIDS-defining opportunistic&#xD;
             disease which is no longer active or progressing will not be grounds for exclusion)&#xD;
&#xD;
          -  Diabetes mellitus, renal failure with uremia, alcohol abuse, previous spinal surgery,&#xD;
             or other documented causes of neuropathy or neuropathic pain&#xD;
&#xD;
          -  Pulmonary disease of sufficient severity to require the use of supplemental oxygen&#xD;
&#xD;
          -  Asthma&#xD;
&#xD;
          -  Life expectancy less than 6 weeks or an active, acute illness likely to interfere with&#xD;
             completion of the study protocol&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Failure to use adequate birth control in an individual with reproductive potential&#xD;
&#xD;
          -  Minority status (less than 21 years), or persons over age 65 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Ellis, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UC San Diego, Hillcrest Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cmcr.ucsd.edu</url>
    <description>Center for Medicinal Cannabis Research</description>
  </link>
  <link>
    <url>http://hnrc.ucsd.edu</url>
    <description>HIV Neurobehavioral Research Center</description>
  </link>
  <verification_date>February 2008</verification_date>
  <study_first_submitted>November 17, 2005</study_first_submitted>
  <study_first_submitted_qc>November 17, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2005</study_first_posted>
  <last_update_submitted>February 20, 2008</last_update_submitted>
  <last_update_submitted_qc>February 20, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2008</last_update_posted>
  <responsible_party>
    <name_title>Ronald J. Ellis, M.D., Ph.D.</name_title>
    <organization>University of California, San Diego</organization>
  </responsible_party>
  <keyword>neuropathy</keyword>
  <keyword>cannabis</keyword>
  <keyword>marijuana</keyword>
  <keyword>HIV</keyword>
  <keyword>DSPN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

